In this article, we will list the 5 Best Large Cap Stocks Under $30 With Highest Upside Potential. Please visit 10 Best Large Cap Stocks Under $30 With Highest Upside Potential if you’d like to see an extended list and the methodology behind it.

5. Aurora Innovation Inc. (NASDAQ:AUR)

Aurora Innovation Inc. (NASDAQ:AUR) is one of the 10 best large cap stocks under $30 with highest upside potential.

On May 29, Northland assigned an Outperform rating to Aurora Innovation Inc. (NASDAQ:AUR) after initiating coverage of the stock and set a price target of $11. This coverage initiation follows rapid advancements in AI models that are currently enabling the deployment of physical agentic AI.

According to the firm, the company is leading this technological shift by deploying 200 superhuman virtual truck drivers this year. Furthermore, Northland views market demand as almost unlimited, noting that the intense technology challenges associated with developing virtual drivers leave the broader industry with only a few viable competitors.

On May 7, an agreement was announced between Aurora Innovation Inc. (NASDAQ:AUR) and Berkshire Hathaway subsidiary McLane Company to begin driverless hauls in Texas. These hauls will feature the Aurora Driver, an SAE level 4 autonomous system that the company is initially deploying within long-haul trucking.

Commenting on the agreement, Aurora President Ossa Fisher stated that the business of moving food is essential to both the economy and our way of life. Fisher highlighted McLane’s 134-year history within the American distribution industry and added that the firm is excited to enter this next chapter to transform the food supply chain using autonomous trucks, describing their collective logistics momentum as palpable.

Aurora Innovation Inc. (NASDAQ:AUR) is a self-driving technology company. It develops and operates Aurora Driver, which is an integrated self-driving platform for freight trucks and commercial vehicles. This platform combines several self-driving hardware, software, and data solutions to operate different types of vehicles.

4. Coupang Inc. (NYSE:CPNG)

Coupang Inc. (NYSE:CPNG) is one of the 10 best large cap stocks under $30 with highest upside potential.

On May 14, J.Q. Dickinson Salt-Works announced its inaugural international expansion strategy by partnering with Coupang Inc. (NYSE:CPNG). The goal is to distribute its signature culinary salts to Asian markets. Following this development, U.S. Congresswoman Carol Miller recently visited the facility, highlighting the critical nexus between foreign trade policy and American technical innovation for growing midsize businesses.

The seventh-generation West Virginia family company can export its locally produced items with ease, without the customary administrative hurdles, by leveraging Coupang’s vast global logistics infrastructure. In particular, the Fortune 150 technology company handles fulfillment, export paperwork, and final delivery in over 190 countries. In 2025, it helped U.S. sellers make over $5 billion in overseas transactions.

Coupang is consistently recognized as a leading global innovator and has the logistical capabilities required for scaling businesses. Going forward, J.Q. Dickinson is committed to sustainably harvesting its exceptionally pure, mineral-rich finishing salt, which is sourced from a 400 million-year-old subterranean sea using conventional sun-drying techniques, while proudly introducing this distinctive Appalachian heritage to millions of new international customers.

Coupang Inc. (NYSE:CPNG) is a technology company based in South Korea that is involved in e-commerce and logistics around the globe. The company leverages its mobile applications and internet websites to deliver various offerings. These include Rocket Fresh, Coupang Eats, Coupang Play, and Farfetch.

3. JBS N.V. (NYSE:JBS)

JBS N.V. (NYSE:JBS) is one of the 10 best large cap stocks under $30 with highest upside potential.

On May 15, Bank of America Securities reduced the firm’s price target on JBS N.V. (NYSE:JBS) from $21 to $20, resulting in almost 66% revised upside potential. The firm also maintained its Buy rating on the stock.

Bank of America Securities informed investors that although it had expected a difficult first quarter scenario for key areas, such as beef and Pilgrim’s Pride, the decline was more than expected. The firm reduced its earnings per share projections for 2026 and 2027 by 24% and 19% each, but stressed that JBS’s size and diverse business strategy could help prevent further losses.

On May 14, JPMorgan adjusted its outlook on JBS N.V. (NYSE:JBS), lowering the price target from $20.50 to $18.50, which resulted in a revised upside potential of over 53%. The firm also downgraded the stock from Overweight to Neutral. This happened right after the earnings report because of what they called weaker momentum.

The firm highlighted that the supply dynamics for the industry have deteriorated immensely in recent times. This is especially true for beef within other regions and also the chicken market in the United States. Because of that, the firm is just going to wait for new catalysts to show up before they recommend buying the shares again.

JBS N.V. (NYSE:JBS) is involved in the processing of animal proteins, including activities related to beef, pork, lamb, and poultry worldwide. The company produces and sells prepared foods and other related products. It also operates in hygiene and beauty products, metal packaging, biodiesel, leather, collagen, and other related businesses. It sells its products under several brand names, including Swift, Pilgrim’s, Seara, Moy Park, and Primo.

2. QXO Inc. (NYSE:QXO)

QXO Inc. (NYSE:QXO) is one of the 10 best large cap stocks under $30 with highest upside potential.

On June 2, QXO Inc. (NYSE:QXO) revealed that, subject to market conditions, its subsidiary, QXO Building Products, plans to offer $3 billion in senior notes, with $1.5 billion payable in 2031 and $1.5 billion in 2034.

The proceeds from the offering shall be kept in an escrow account and will be covered on the basis of first priority. This applies if the notes are issued prior to QXO completing its planned acquisition of TopBuild. Customary requirements, such as approval from QXO and TopBuild shareholders, still apply to the transaction.

QXO Building Products aims to utilize the proceeds from this offering, along with other borrowings and issuance proceeds, for the acquisition of TopBuild. The acquisition will also involve the utilization of existing balance sheet cash.

On May 14, Stephens revised its view of QXO Inc. (NYSE:QXO) following the company’s latest quarterly earnings report. The firm reduced its price target from $29 to $26. But it still chose to maintain an Overweight rating on the shares, which offer an adjusted upside potential of over 58%.

The latest financial results matched expectations perfectly with no real surprises. The firm noted that the company’s internal projects to improve margins are finally coming together and will look a lot better in the coming months.

QXO Inc. (NYSE:QXO) is a tech-enabled distributor of building products such as roofing, waterproofing, materials, and related supplies. It markets its offerings through contractors, distributors, and suppliers. The company is currently in an aggressive pursuit of its inorganic growth strategy, with the aim of expanding the topline to $50 billion within the next decade.

1. Summit Therapeutics Inc. (NASDAQ:SMMT)

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 best large cap stocks under $30 with highest upside potential.

On May 31, Summit Therapeutics Inc. (NASDAQ:SMMT) presented new clinical data from the international Phase II AK112-206 trial during the American Society of Clinical Oncology. Co-sponsored alongside Akeso, this multisite study evaluates the potential first-in-class bispecific antibody named ivonescimab, for patients battling first-line metastatic colorectal cancer.

According to the study, treatment-naive patients in the U.S. and China receiving this novel therapeutic in combination with standard mFOLFOX6 chemotherapy showed a strong objective response rate of 70.8%. When compared to the previous performance of standard-of-care regimens that mix bevacizumab with traditional FOLFOX chemotherapy, it is seen that these clinical outcomes are quite promising.

On May 1, the price target on Summit Therapeutics Inc. (NASDAQ:SMMT) was cut from $17 to $16 by Piper Sandler. The firm retained a Neutral rating on the stock. According to the company’s first-quarter earnings report, the projected quarter two preliminary PFS analysis was completed and approved by the IDMC, which suggested that the research should proceed as scheduled.

Despite little alpha expended in the interim, Summit shares are “understandably weak” after-hours, according to the firm, as investors wonder if the remarkable effect size seen in Akeso’s HARMONi-6 can be repeated in Summit’s worldwide HARMONi-3 trial.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a clinical-stage biopharma company that develops and commercializes medical oncology therapies. It is focused on developing ivonescimab, a bispecific antibody that combines blockade of PD-1 and anti-angiogenesis in a single molecule. It is also running Phase III clinical trials for the treatment of non-small lung cancer.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.